Hence, the assumption has been that these patients would be relatively free of the positive symptoms of schizophrenia that might Ulixertinib solubility dmso complicate the assessment of cognitive deficits and impede the ability of patients to benefit from cognitive enhancers. The MATRICS consensus process MATRICS consisted of a series of conferences organized by corresponding committees of experts. The first step was taken by the MATRICS Neurocognition Committee, which organized

a 2-day consensus meeting in April 2003 in order to identify the critical domains of cognitive deficits that Inhibitors,research,lifescience,medical characterize patients with schizophrenia.6 The seven domains of cognition deemed most relevant in schizophrenia were: working memory; attention/vigilance; Inhibitors,research,lifescience,medical verbal learning and memory; visual learning and memory; speed of processing; reasoning and problem-solving; and social cognition. At the second MATRICS meeting, held at the National Institutes of Health (NIH) in June of 2003, the Neuropharmacology Committee assembled Inhibitors,research,lifescience,medical clinicians and psychopharmacologists from academia and industry to identify the most intriguing molecular targets, promising compounds, relevant human test measures, and potentially predictive animal models for use in the discovery of treatments that target basic mechanisms related to complex cognitive operations.

The presentations at that meeting were gathered in a special issue of Psychopharmacology.7 A third MATRICS conference then used the consensus process developed by RAND Health to develop recommendations for the appropriate cognitive Inhibitors,research,lifescience,medical tests to be used in clinical assessments of potential

cognitive enhancers. The meeting resulted in a beta version of the MATRICS Consensus Inhibitors,research,lifescience,medical Cognitive Battery for Clinical Trials, which is listed on the MATRICS Web site.8,9 The next MATRICS meeting was held at the NIMH in January 2004 and focused on collaborations between the NIMH and industry. The fifth MATRICS conference involved a joint meeting between the FDA and the NIMH, and addressed the processes needed for assessment of cognition as an end point in clinical trials. This meeting was held at the NIH in April 2004 and was summarized already in Buchanan et al.10 Once the primary consensus-building goals of MATRICS were accomplished, a concluding meeting called “New Approaches to Assessing and Improving Cognition in Schizophrenia” was held in Potomac, Md, in September 2004. This meeting was designed to look ahead in order develop a research agenda that would foster improved methods for the discovery, validation, and assessment of procognitive cotreatments for schizophrenia (for transcripts of the presentations, see the MATRICS Web site9). The proceedings of this last MATRICS conference were summarized in a special issue of Schizophrenia Bulletin.